Remedium Capital Partners, LLC

WEST PALM BEACH, FL · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$273.6M2026 Q3
Positions6
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.100.0%

Remedium Capital Partners, LLC reported 6 positions worth $273.6M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: SYRE (37.8%). Biggest move: exit Apogee Therapeutics Inc ($77.9M).

6 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 SYRESpyre Therapeutics$103.3M37.77%1,160,620——+16.8%
▸ 2 ORKAOruka Therapeutics$79.5M29.05%954,150——+19.1%
▸ 3 DMRADamora Therapeutics$43.5M15.91%2,045,473——+1.5%
▸ 4 JBIOJade Biosciences$25.4M9.28%1,807,814———
▸ 5 KRSAKorsana Biosciences$16.6M6.07%518,500———
▸ 6 CBIOCrescent Biopharma$5.3M1.93%361,250——-3.0%

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Remedium Capital Partners, LLC hold as of Q3 2026?

Remedium Capital Partners, LLC reported 6 positions worth $273.6M in its Q3 2026 13F filing. Largest positions: SYRE (37.8%), ORKA (29.0%), DMRA (15.9%), JBIO (9.3%) and KRSA (6.1%).

What did Remedium Capital Partners, LLC buy in Q3 2026?

New positions: DMRA and KRSA. Added to: JBIO.

What did Remedium Capital Partners, LLC sell in Q3 2026?

Reduced: ORKA and SYRE. Sold out entirely: Apogee Therapeutics Inc and Damora Therapeutics Inc.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.